TNF and psoriasis: Currently, biologics targeting TNF-α, IL-12/IL-23 p40, IL-23p19, IL-17A, and IL-36R are used in the clinical treatment of psoriasis, and they are superior in terms of efficacy than nonbiological treatment [9,10].